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Background: Anterior cervical discectomy with interbody fusion cages is considered the standard surgical
procedure in patients with cervical disc herniation. However, PEEK or metal cages have some undesirable imaging
characteristics, leading to a search for alternative materials not creating artifacts on images; silicon nitride ceramic.
Whether patients treated with silicon nitride ceramic cages have similar functional outcome as patients treated with
PEEK cages is not known. We present the design of the CASCADE trial on effectiveness of ceramic cages versus
PEEK cages in patients with cervical disc herniation and/or osteophytes.
Methods/Design: Patients (age 18–75 years) with monoradicular symptoms in one or both arms lasting more than
8 weeks, due to disc herniation and/or osteophytes, are eligible for the trial. The study is designed as a randomized
controlled equivalence trial in which patients are blinded to the type of cage for 1 year. The total follow-up period
is 2 years. The primary outcome measure is improvement in the Neck and Disability Index (NDI). Secondary
outcomes measures include improvement in arm pain and neck pain (VAS), SF-36 and patients' perceived recovery.
The final elements of comparison are perioperative statistics including operating time, blood loss, length of hospital
stay, and adverse events. Lateral plane films at each follow-up visit and CT scan (at 6 months) will be used to judge
fusion and the incidence of subsidence. Based on a power of 90% and assuming 8% loss to follow-up, 100 patients
will be randomized into the 2 groups. The first analysis will be conducted when all patients have 1 year of follow-
up, and the groups will be followed for 1 additional year to judge stability of outcomes.
Discussion: While the new ceramic cage has received the CE Mark based on standard compliance and animal
studies, a randomized comparative study with the golden standard product will provide more conclusive
information for clinicians. Implementation of any new device should only be done after completion of randomized
controlled effectiveness trials.
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Figure 1 Valeo C+CSC cervical interbody fusion device.
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Since the introduction of anterior approach to the cer-
vical spine by Cloward [1] and Smith [2], a dispute has
arisen about the best surgical treatment. The purpose of
all anterior cervical surgical procedures is removal of the
intervertebral disc in order to decompress the nerve root
and alleviate radicular pain and/or myelopathy. However,
cervical instability and segmental collapse with recurrent
radicular pain has been documented after anterior disc-
ectomy. For this reason, most surgeons perform anterior
discectomy with interbody fusion (ACDF) although there
is controversy about the benefits of adding interbody
fusion to the cervical discectomy technique [3-9].
Anterior discectomy with fusion (ACDF) using bone
graft in dowel or block form can have complications as-
sociated with graft collapse and can be associated with
pain at the donor site if the graft is harvested from the
iliac crest [10]. Interbody fusion using metal or plastic
cages to contain and reinforce bone graft has been
shown to have several advantages over bone blocks [11]:
1) using a cage allows the surgeon to fill the space with-
out harvesting bone from the iliac crest in most cases;
local bone or a bone graft substitute can be used instead;
2) the strength of the cage material ensures preservation
of the disc height; bone blocks can crumble, decreasing
the disc height with consequent neuroforaminal stenosis;
and 3) using a cage saves time in the operating room
and reduces blood loss. If there is no iliac crest bone
graft harvest, there is less postoperative pain, as well.
Both plastic and metal cages have disadvantages as
well. The principal plastic material, polyetheretherketone
(PEEK), is hydrophobic and a mild chronic fibrous tissue
reaction develops around the implant [12]. PEEK is
invisible on imaging and therefore dislodgement and
subsidence are difficult to determine. The two most
commonly used metals, stainless steel and titanium dis-
tort magnetic resonance imaging (MRI) and CT scans,
making determination of fusion and evaluation of degen-
eration difficult[13,14]. At present, ACDF with a PEEK
cage is considered the golden standard for cervical disc
herniation by many surgeons [15,19].
Recently, ceramic materials have been evaluated as
alternatives for interbody fusion devices. The cortical
ring of the new device is manufactured by study sponsor
Amedica Corporation (Salt Lake City, Utah) from its
proprietary “MC2” silicon nitride (Si3N4) ceramic. MC
2
silicon nitride ceramic is a hydrophilic negative charged
ceramic, which means that fluid (blood with nutrients)
and proteins attach to the material, facilitating bone cell
adherence and incorporation of the material in the sur-
rounding bone. Cancellous Structured Ceramic (CSC) is
a porous version of the same MC2 silicon nitride cer-
amic (Figure 1). Therefore, the entirety of this device is
manufactured from identical material. The CSC materialfills the center hole for the purpose of providing a scaf-
fold for bone ingrowth. Because the surgical technique
of this device does not involve harvesting autograft for
packing into the pores of the porous trabecular struc-
ture, these implants afford the possibility of avoiding
harvesting iliac crest autograft with attendant benefits of
avoiding patient co-morbidities. Moreover, the silicon
nitride material has desirable imaging properties. It is
visible (like cortical bone) but does not create an artifact
on CT or MR images (Figure 2).
The Valeo C+CSC cage has received the CE Mark
based on preclinical testing and standards compliance,
but has not been evaluated in a clinical study. Good clin-
ical practice means that every new device should be
compared to the golden standard prior to implementa-
tion of the device on a large scale. Therefore, it is neces-
sary to perform a randomized controlled effectiveness
trail on Valeo C+CSC versus PEEK cages. In the CAS-
CADE (CAncelous Structured Ceramic Arthrodesis
DEvice) trial, we will randomly and blindly compare an-
terior discectomy with ceramic cages versus anterior
discectomy with PEEK cages. In this equivalence trial,
we hypothesize similar effectiveness and no difference in
clinical improvement between the ceramic cage and the
PEEK cage as measured with the Neck Disability Index
(NDI). Moreover, radiological properties will be docu-
mented focusing on fusion and subsidence.
Methods/design
The study is designed as single center randomized con-
trolled trial in which patients will be blinded for the
allocated treatment. The follow-up period will be 2
years. All patients between 18 and 75 years old with
monoradicular symptoms in one or both arms lasting
Figure 2 Silicon nitride, titanium, PEEK and trabecular metal imaging characteristics in a human cadaveric vertebra (unpublished data).
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confirm cervical disc herniation and/or osteophytes in
accordance with clinical symptoms. Additional inclusion
and exclusion criteria are listed in Table 1.
Patients are referred by a neurologist with MRI of the
cervical spine. During the first visit to the neurosurgical
outpatient clinic, the patient’s history and a standard
neurological examination will be documented. Based on
our selection criteria, the neurosurgeon decides whether
a patient is eligible for the trial.
Informed consent and patients’ safety
The patient’s written informed consent is obtained. The
patient will be notified that they are free to withdraw
their consent at any time. An independent physician has
been appointed to answer patient questions and monitor
the study, when necessary. Adverse events or complica-
tions will be monitored and followed up until stable or
resolved. The project will be conducted according to the
guidelines of Good Clinical Practice. The study has been
reviewed and approved by the Medical Ethics Commit-
tee (METC) of Southwest Holland.
Randomization procedure
In order to eliminate confounding factors, the study is
designed as a randomized controlled trial. Patients will
be randomly allocated to the Valeo C+CSC or PEEK
cages. Randomization will take place in the operating
room within 6 weeks after inclusion. A randomization
list was prepared by the data manager. A random
numbergenerator was used to create the allocation se-
quence of blocks of 4, 6, and 8 to ensure equal distribu-
tion of the randomized treatments. The data manager,
who is not involved in the selection and allocation of
patients, prepared numbered, coded, sealed envelopescontaining the treatment allocation. In the operating
room, after induction of anaesthesia, the surgeon will
open the next numbered envelope and the allocated
treatment will be performed. Patients will be kept
blinded for the allocated treatment for 1 year.Surgical intervention
All patients will be operated by the authors MA or JW,
who both have extensive experience in cervical spine
surgery and this ACDF technique. The patients will be
positioned supine with their neck in neutral position or
slightly extended under general anaesthesia. The affected
cervical disc level will be verified with fluoroscopy. A
small transverse incision will be made on the right side.
Medial to the carotid sheath, the pre-vertebral space will
be opened and the anterior cervical spine will be ex-
posed. Caspar spreader and 2 distraction pins will be
placed in the affected segment. A standard anterior disc-
ectomy with the aid of loupe magnification or micro-
scope (depending on the surgeon’s preference) will be
performed in all cases. The posterior longitudinal liga-
ment will be opened and the nerve root and dura will be
decompressed adequately. Once the anterior discectomy
has been performed, a PEEK interbody cage (Medicrea
Manta, Lyon, France) (group 1) filled with local bone
[20] obtained from removal of osteophytes, or the Valeo
C+CSC spacer (Amedica Corporation, Salt Lake City,
Utah) (group 2) will be placed within the intervertebral
space under fluoroscopic guidance. The CSC core
should be smeared with blood obtained by scratching
the end plate after the disc space is prepared. No supple-
mental fixation (e.g., cervical plate) will be used in the
procedure. If required, a vacuum drain will be placed
and the wound will be closed in layers.
Table 1 Selection criteria for trial eligibility
Inclusion criteria
• Age 18-75 years
• Radicular signs and symptoms in one or both arms (i.e., pain,
paresthesia or paresis in a specific nerve root distribution) or
symptoms and signs of acute or chronic myelopathy
• At least 8 weeks prior conservative treatment (i.e., physical
therapy, pain medication)
• Radiographic diagnosis of cervical disc herniation and/or
osteophyte at 1 level (C3-C4 to C7-T1) in accordance with clinical
signs and symptoms
• Ability and willingness to comply with project requirements
• Written informed consent given by the subject or the subject's
legally authorised representative
Exclusion criteria
• Previous cervical surgery (either anterior or posterior)
• Increased motion on dynamic studies (> 3 mm)
• Severe segmental kyphosis of the involved disc level (> 7
degrees)
• Patient cannot be imaged with MRI
• Neck pain only (without radicular or medullary symptoms)
• Infection
• Metabolic and bone diseases (osteoporosis, severe osteopenia)
• Neoplasm or trauma of the cervical spine
• Spinal anomaly (Klippel Feil, Bechterew, OPLL)
• Severe mental or psychiatric disorder
• Inadequate Dutch language
• Planned (e)migration abroad in the year after inclusion
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Baseline assessments include demographics, work status,
smoking status, neck and arm pain, history of neck
trauma, medical history, pain medication, body mass
index, and neurological signs and symptoms. A general
physical and neurological examination is performed be-
fore the patient is enrolled into the study and will be re-
peated at each subsequent visit.
We will assess the below described validated outcome
parameters. Patients will not be informed about their
previous scores. Follow-up examinations will take place
by the surgeon at 3 months, 6 months, 12 months, and
24 months after randomization. The schedule of follow-
up visits, radiographic studies and outcomes measures is
included in Table 2. The following measures of out-
comes will be used:
1) Neck Disability Index (primary outcome measure):
The NDI is a patient-completed 10-item
questionnaire on 3 different aspects; pain intensity,
daily work related activities and non-work related
activities. Each item is scored from 0 to 5 and the
total score ranges from 0 (best score) to 50 (worstscore). The NDI is a modification of the Oswestry
Disability Index and has been shown to be reliable
and valid for patients with cervical pathology [21,22]
and has been validated in the Dutch language [23].
2) Short-Form 36 (SF-36): The SF-36 [24] is a generic
health status questionnaire that can easily be filled out
by the patient at home. The questionnaire consists of
36 items on physical and social status of the patient
subdivided in 8 domains; 1) physical functioning,
2) physical restrictions, 3) emotional restrictions,
4) social functioning, 5) somatic pain, 6) general
mental health, 7) vitality and 8) general health
perception. The questions are scored on a scale of 0
(worst health) to 100 (ideal health). This questionnaire
has been used frequently and is validated in surgical
studies on spine pathology [25,26].The Dutch
language version has also been validated [27].
3) Pain intensity, measured by Visual Analogue Score
(VAS) of arm and neck. The VAS of arm pain will
measure the experienced pain intensity in the arm
during the week before visiting the researcher. Pain
will be assessed on a horizontal 100 mm scale varying
from 0 mm (no pain) to 100 mm (worst pain
imaginable). Patients do not see the results of earlier
assessments and will score the pain experienced at the
visit. Since many patients with radicular arm pain
have neck pain as well, we will also measure the
intensity of solitary neck pain. Reliability, validity and
responsiveness of VAS have been shown [28].
4) Perceived recovery: Likert Scale is a 7-point scale
measuring the perceived recovery, varying from
‘complete recovery’ to ‘worse than ever’. This
outcome scale has been used in previous studies and
has been shown to be valid and responsive to
change [29]. “Complete recovery” and “almost
complete recovery” are defined as good result.
5) Radiological outcome: Anterior/posterior, and lateral
views of the cervical spine will be performed at each
visit. Displacement or subsidence of the device will
be assessed by using the lateral radiograph. Only a
change of >3 mm will be considered clinically
significant due to the margin of error in radiographic
determination of displacement distances.
Radiolucency at the cage-bone interface will be
assessed as either present (if extending 50% of the
length of the cage) or absent using a standard lateral
radiograph. To verify fusion, CT axial images at 2 mm
slices will be taken at the 6 months visit only.
6) Other outcome measures: In addition to the
outcomes measures, data will be captured on details
of the surgical procedure and hospitalization such as
type and size of implant, duration of surgery,
estimated blood loss, operative and postoperative
complications, day of mobilization, and duration of
Table 2 Data collection and outcome measures
Measure Pre-Op Intra-Op 3 months 6 months 12 months 24 months
Inclusion / exclusion criteria x
Product use, operative time, blood loss x
Neurological examination x x x x x
Neck Disability Index, Arm Pain VAS, Neck Pain VAS, SF-36, Recovery Likert x x x x x
Radiographs X-ray x x x x x
CT scan x
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also be recorded by the operating surgeon.
The de-identified data from the initial visits, hospita-
lization and follow-up visits are entered by research
nurses and physician assistants into a database via an
Electronic Data Capture system (Acumen Healthcare
Solutions, LLC, Plymouth, Minnesota, USA). Hospital
staff schedules follow-up visits and supervises the collec-
tion of the patient-completed data forms. The source
documents are kept filed in the hospitals where the pro-
cedures are performed.
Participating patients are given a small stipend to
cover travel costs for follow-up visits. The cost of the
procedure (including the interbody fusion devices) is
covered by the patient’s health insurance, but the ex-
pense of extra imaging and radiologist fees are paid by
the study sponsor.
Sample size and data analysis
Sample size for this equivalence trial has been estab-
lished using power analysis incorporating data from
journal article reports of similar ACDF studies. For sam-
ple size calculations, we have used the change in NDI
from pre-op to one year post-op cited in the literature
for ACDF with carbon fiber reinforced PEEK cages: 10%
reduction (improvement) with a standard deviation of
22% [30]. The Minimal Clinically Important Difference
(MCID) for the NDI is 7.5 points or 15% [31], which is
the equivalence interval for sample size calculation. A
46-patient Valeo C enrollment has a power of .90 when
compared with a PEEK study arm of the same size. In-
corporating a one-year estimate of 8% loss to follow up,
a total of 100 patients need to be enrolled.
The statistical significance of categorical data such as
fusion will be tested using the Pearson Exact test. Para-
metric data will be evaluated using the Student’s t-test.
The first data analysis will be performed when all of the
1-year follow-up data is available for the primary end-
point. The two groups will be considered equivalent if
the mean NDI improvement for the silicon nitride cage
group is within a range from the mean of the PEEK
group minus the NDI MCID to the PEEK mean plus the
MCID. A repeated measurements analysis of variancefor the primary outcome measure will also be performed
in order to compare the evolving patterns over time.
The inclusion period started in December 2011 and
2-year follow-up measures will be completed by the end
of 2014.
Discussion
A cervical radicular syndrome due to disc herniation is a
well-known entity with an annual incidence rate of 83
per 100,000. Patients usually present with radicular arm
pain and paraesthesiae, with or without neck pain. More
than 90% of the patients have a favourable outcome with
conservative treatment only [32] .Surgery is indicated
whenever disabling pain persists. Anterior cervical disc-
ectomy (ACD) is the basic surgical treatment of patients
with radicular pain caused by cervical disc herniation. In
1958, Cloward first described anterior cervical decom-
pression with the use of autologous iliac crest interbody
graft (ACDF) to maintain disc height [1]. Smith and
Robinson developed a technique using iliac crest bone
blocks that was the standard for many year [2].There is
still controversy about the benefits of adding interbody
fusion to the cervical discectomy technique [4,10,33,34].
Frequently surgeons perform ACDF to maintain disc
height and cervical alignment, and promote bony fusion
to prevent instability [25].
Various prospective randomised trials have been
performed comparing anterior discectomy with add-
itional interbody fusion [3-9]. These results suggest that
interbody fusion may not be necessary in all cases. How-
ever, definite conclusions could not be drawn due to
methodological flaws such as small sample size, non-
homogenous patient population, undefined randomisa-
tion procedures and inconsistent outcome measures.
Two large randomized trials are currently addressing the
question of the value of adding fusion or cervical total
disc replacements to the cervical discectomy procedure
[35,36]. It is anticipated that ACDF will still be a viable
choice for many patients even after these trials are
completed.
Although there is no consensus on which interbody
device to use, currently PEEK cages are considered as
the golden standard for anterior cervical discectomy
with fusion by many surgeons [15-19]. However, PEEK
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istics that result in a demand for better cages with simi-
lar effectiveness. Figure 2 illustrates the superior imaging
properties of MC2 ceramic material compared to PEEK,
titanium and trabecular metal. Moreover, the CSC ma-
terial fills the center hole for the purpose of providing a
scaffold for bone ingrowth resulting in solid fusion and
no subsidence of the cage. The CSC form of the material
has performed well in an animal model [37] but the re-
sults and effectiveness need to be validated in humans.
It is possible that solid fusion without signs of subsid-
ence may lead to improved clinical outcome.
The present protocol of the CASCADE trial is
designed to demonstrate the effectiveness and security
of cancellous structured ceramic cages compared to the
golden standard PEEK cages in patients treated with
anterior cervical discectomy and fusion. Worldwide
implementation of new devices should only be done
after completion of randomized controlled trials. In our
opinion, Level 1 evidence that government and health
insurance organizations are demanding would not be
possible without close cooperation between industry and
researchers, but transparency is warranted and relevant
conflicts of interest must be disclosed.
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